Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Peregrine Rises on Agreement for Late-Stage Study

By Pharmaceutical Processing | May 21, 2013

WASHINGTON (AP) — Shares of Peregrine Pharmaceuticals Inc. surged Monday after the company said it would move ahead with a late-stage trial of its lead product, the experimental lung cancer treatment bavituximab.

THE SPARK: Peregrine said in a release it reached an agreement with the Food and Drug Administration on a phase III study of its drug involving 600 patients. The trial will enroll patients with non-small cell lung cancer whose disease has progressed after treatment with standard therapy. The study will evaluate bavituximab based on patients’ overall survival.

The Tustin, Calif.-based drugmaker said it would present final data from its mid-stage studies of the drug at a meeting for cancer specialists on June 1.

THE BIG PICTURE: Peregrine does not have any approved products and bavituximab is its most advanced experimental drug. In early September Peregrine said patients who were treated with bavituximab lived twice as long as patients who received only chemotherapy in a clinical trial.

A few weeks later the company said it had found problems with the reported trial data and its initial analysis couldn’t be relied on. Peregrine said the problem appeared to be tied to another company that was contracted to code and distribute the product. In January Peregrine reported that the discrepancies are limited to a single dose of the drug.

SHARE ACTION: Peregrine shares rose 34 cents, or 22 percent, to $1.88 in trading Monday.

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE